Loading
Etoposide is a chemotherapy from the mayapple plant, essential to curing testicular cancer (BEP), treating small-cell lung cancer, lymphomas, childhood sarcomas and leukaemias, and used in transplant conditioning.
Approved 1983. BEP/EP (germ cell), platinum-etoposide (SCLC, neuroendocrine carcinoma), VDC/IE (Ewing), ICE/DHAP salvage (lymphoma), EPOCH, HLH and Wilms/neuroblastoma regimens, EMA-CO (GTN), oral etoposide palliation, high-dose conditioning (BEAM). Secondary AML with 11q23 (KMT2A) rearrangement is a recognised late effect.
Stabilises topoisomerase II-DNA cleavage complexes, producing double-strand breaks in S/G2; schedule-dependent (multi-day dosing). Connects to KMT2A (MLL) rearrangement.
1.Etoposide slips into a pocket on KMT2A (MLL) rearrangement.
Oral anticancer drug with an injectable equivalent used for the same indication, so Medicare covers the oral form under Part B (the oral anticancer drug benefit) as well as under Part D; the pharmacy bills whichever applies. IV etoposide is Part B.
Multi-source generic; covered under the medical benefit without prior authorisation in most plans, as part of standard regimens.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B) · Medicare.gov: Drug coverage (Part D) · Medicare.gov: Costs for Medicare drug coverage (annual out-of-pocket cap). Not medical or financial advice; verify with your plan.
Sources: NICE search: etoposide. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 1983 | Refractory testicular tumours; small-cell lung cancer (1986) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
For fit younger patients treated in the intensive German tradition, BrECADD replaces escalated BEACOPP; how it compares with nivolumab-AVD from S1826 is the open question.
The standard-of-care rows on all three trophoblastic pages follow this report and the national centres it describes.
Paclitaxel with antiretroviral therapy is the treatment to supply for advanced AIDS-associated Kaposi sarcoma in resource-limited settings; cheaper regimens are inferior.
R-CHOP remains the standard first-line regimen for diffuse large B-cell lymphoma. The trial is also the clearest lesson in the disease about adopting a regimen on single-arm data: dose-adjusted EPOCH-R had been used widely for a decade before this comparison existed.
Immunotherapy is now part of first-line treatment for extensive-stage small-cell lung cancer everywhere, on the strength of a gain measured in weeks. The size of that gain is the reason small-cell lung cancer remains the clearest unmet need in thoracic oncology.
Sinonasal undifferentiated carcinoma is treated with induction platinum-etoposide, and the response decides whether the patient is spared radical surgery.
Women with poor-prognosis placental-site or epithelioid trophoblastic tumours should be referred to a specialist centre where intensified and experimental treatments, including immunotherapy, are available.
Confirmation, by a different route from HD18, that the interim scan can safely direct de-escalation in advanced Hodgkin lymphoma, and that most of the toxicity of escalated BEACOPP can be avoided in the 84 per cent of patients who respond early.
Query for this drug: (TITLE:"Etoposide" OR ABSTRACT:"Etoposide" OR TITLE:"VePesid" OR ABSTRACT:"VePesid" OR TITLE:"Etopophos" OR ABSTRACT:"Etopophos" OR TITLE:"Toposar" OR ABSTRACT:"Toposar") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Etoposide, not a curated reading list.
Shares ACTG A5263/AMC 066: three chemotherapy regimens with antiretroviral therapy for advanced AIDS-associated Kaposi sarcoma in resource-limited settings, EMA/CO for high-risk gestational trophoblastic tumours: results from a cohort of 272 patients, ACTG A5263/AMC 066, Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma and the tags generic, who-essential.
Shares Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE), EMA/CO for high-risk gestational trophoblastic tumours: results from a cohort of 272 patients, Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma, EuroNet-PHL-C2 and the tags generic, who-essential.
Shares Treatment of disseminated germ cell tumours with cisplatin, bleomycin and either vinblastine or etoposide, ACTG A5263/AMC 066: three chemotherapy regimens with antiretroviral therapy for advanced AIDS-associated Kaposi sarcoma in resource-limited settings, ACTG A5263/AMC 066, Yolk sac tumour of the testis, postpubertal type and the tags generic, who-essential.
Shares EMA/CO for high-risk gestational trophoblastic tumours: results from a cohort of 272 patients, FIGO Cancer Report 2021: diagnosis and management of gestational trophoblastic disease, Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia, Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents and the tags generic, who-essential.
Shares EMA/CO for high-risk gestational trophoblastic tumours: results from a cohort of 272 patients, FIGO Cancer Report 2021: diagnosis and management of gestational trophoblastic disease, COG AREN0533, Placental-site trophoblastic tumour and epithelioid trophoblastic tumour and the tags generic, who-essential.
Shares Treatment of disseminated germ cell tumours with cisplatin, bleomycin and either vinblastine or etoposide, Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma, Extragonadal germ cell tumour, AHL2011 and the tags generic, who-essential.
Shares A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors, GETUG 13, Extranodal NK/T-cell lymphoma, Generic sterile injectables (the 2023 platinum shortage) and the tags generic, who-essential.
Shares High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN), Rhabdomyosarcoma, High-risk neuroblastoma, Ewing sarcoma and the tags generic, who-essential.